CD274 and head and neck squamous cell carcinoma: Treatment naïve patients with advanced/metastatic HNSCC expressing PD-L1 (CPS ≥ 1) are randomized to receive pembrolizumab with GSK3359609 or placebo in the INDUCE-3 trial (NCT04128696).